Gastroenterology
Latest news
416 articles · 20 / page
Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial
The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o
Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma
The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresecta
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics
A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight mana
Precision Genomics Outperforms Empirical Approaches in Managing Drug-Resistant Helicobacter pylori
A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.
Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer
A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported q
Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?
The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological im
Tracking the Immune Pulse: Why mHLA-DR Trajectories Predict Survival in Sepsis and Liver Transplantation
Large-scale cohort and prospective data reveal that monocyte HLA-DR expression is a dynamic predictor of ICU-acquired infections and mortality, offering a roadmap for personalized immunostimulant therapy in septic shock and transplant patie
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants
A large-scale cohort study demonstrates that mixed-type IPMNs have a three-fold higher prevalence of high-risk mutations compared to branch-duct variants, and that cyst fluid NGS provides superior diagnostic specificity over traditional cli
Combined Gastric Electrical Stimulation and Pyloroplasty Achieve Superior Symptom Relief in Refractory Gastroparesis
A randomized clinical trial demonstrates that combining gastric electrical stimulation with pyloroplasty significantly outperforms pyloroplasty alone, providing superior symptom relief and reducing hospitalizations for patients with medicat
Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis
A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized
Optimized Bismuth Quadruple Therapy Surpasses Standard Triple Therapy for First-Line H. pylori Eradication
A double-blind RCT in Chile demonstrates that a 14-day optimized bismuth quadruple therapy achieves a 95% eradication rate for Helicobacter pylori, significantly outperforming standard triple therapy without increasing the burden of adverse
Probiotics Cut Clostridioides difficile Risk in Antibiotic-Exposed Patients — Small Benefit, Low Certainty
A 2025 Cochrane update finds probiotics may halve the relative risk of C. difficile-associated diarrhea in antibiotic-treated patients (ARR 1.6%, NNT 65) but evidence is low certainty and applicability varies with baseline risk.
Intraperitoneal Chemotherapy for Gastric Cancer: Promising Survival Signals but Very Low‑Certainty Evidence
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias,
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy
Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-sp
Condition-Specific Growth Charts and a New Medical Therapy for Alagille Syndrome: Implications for Growth Assessment and Symptom Control
Two recent multicenter studies provide condition-specific growth charts for children with Alagille syndrome and show that ileal bile acid transporter inhibition with odevixibat reduces pruritus and serum bile acids — reshaping growth assess
Proton Pump Inhibitor Use and Survival Outcomes in Newly Diagnosed Glioblastoma: An Evidence-Based Review
Proton pump inhibitor use, particularly potent ALDH1A1-activating PPIs, is associated with worse survival in newly diagnosed glioblastoma, highlighting the need for cautious use and further mechanistic research.
Midline Paracentesis May Lower Bleeding Risk: Evidence From a 4,500‑Procedure Retrospective Review
A large single‑center retrospective review found zero hemorrhagic complications after midline ultrasound‑guided paracentesis versus 60 events after lateral approaches (0/230 vs 60/4,283; p=0.03), suggesting the midline (linea alba) approach
Glecirasib, Alone and with Cetuximab, Shows Activity in KRASG12C-Mutant Colorectal Cancer — Combination Nearly Doubles Response Rate
Phase 1/2 data show oral glecirasib has single-agent activity (ORR 23%) in KRASG12C colorectal cancer; adding cetuximab raises ORR to 50% with manageable toxicity, supporting further randomized testing and earlier-line combination strategie
Browse by specialty
Open language-specific specialty feeds and department pages.